Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2011, Article ID 510398, 8 pages
http://dx.doi.org/10.4061/2011/510398
Clinical Study

Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study

1Department of Medical Research, Pharmaserve-Lilly, Kifissia, 14564 Athens, Greece
2Rheumatology Department, Veterans Administration Hospital, 11521 Athens, Greece

Received 27 January 2011; Revised 20 April 2011; Accepted 19 July 2011

Academic Editor: Stuarts L. Silverman

Copyright © 2011 K. Aloumanis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. S. Browner, A. R. Pressman, M. C. Nevitt, and S. R. Cummings, “Mortality following fractures in older women: the study of osteoporotic fractures,” Archives of Internal Medicine, vol. 156, no. 14, pp. 1521–1525, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. M. C. Nevitt, B. Ettinger, D. M. Black et al., “The association of radiographically detected vertebral fractures with back pain and function: a prospective study,” Annals of Internal Medicine, vol. 128, no. 10, pp. 793–800, 1998. View at Google Scholar · View at Scopus
  3. C. Cooper, F. Jakob, C. Chinn et al., “Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO),” Osteoporosis International, vol. 19, no. 4, pp. 493–501, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Sanfélix-Genovés, I. Hurtado, G. Sanfélix-Gimeno, B. Reig-Molla, and S. Peiró, “Impact of osteoporosis and vertebral fractures on quality-of-life. A population-based study in Valencia, Spain (The FRAVO Study),” Health and Quality of Life Outcomes, vol. 9, article 20, 2011. View at Publisher · View at Google Scholar
  5. S. R. Cummings and L. J. Melton, “Osteoporosis I: epidemiology and outcomes of osteoporotic fractures,” The Lancet, vol. 359, no. 9319, pp. 1761–1767, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Johnell and J. A. Kanis, “An estimate of the worldwide prevalence and disability associated with osteoporotic fractures,” Osteoporosis International, vol. 17, no. 12, pp. 1726–1733, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Kanis and O. Johnell, “Requirements for DXA for the management of osteoporosis in Europe,” Osteoporosis International, vol. 16, no. 3, pp. 229–238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. P. D. Delmas, “Treatment of postmenopausal osteoporosis,” The Lancet, vol. 359, no. 9322, pp. 2018–2026, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Sambrook and C. Cooper, “Osteoporosis,” The Lancet, vol. 367, no. 9527, pp. 2010–2018, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. R. M. Neer, C. D. Arnaud, J. R. Zanchetta et al., “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis,” The New England Journal of Medicine, vol. 344, no. 19, pp. 1434–1441, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. K. G. Saag, E. Shane, S. Boonen et al., “Teriparatide or alendronate in glucocorticoid-induced osteoporosis,” The New England Journal of Medicine, vol. 357, no. 20, pp. 2028–2039, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Dowd, R. R. Recker, and R. P. Heaney, “Study subjects and ordinary patients,” Osteoporosis International, vol. 11, no. 6, pp. 533–536, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Rajzbaum, F. Jakob, D. Karras et al., “Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting,” Current Medical Research and Opinion, vol. 24, no. 2, pp. 377–384, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. B. L. Langdahl, G. Rajzbaum, F. Jakob et al., “Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS),” Calcified Tissue International, vol. 85, no. 6, pp. 484–493, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Karras, V. Drossinos, C. Barker et al., “Baseline characteristics and quality of life evaluation in Greek women with osteoporosis enrolled in the European Teriparatide Observational Study (EFOS),” Bone, vol. 20, no. 3, article 156, 2009. View at Google Scholar
  16. A. Szende and A. Williams, Eds., Measuring Self-Reported Population Health: An International Perspective Based on EQ-5D, Springmed, Budapest, Hungary, 2004.
  17. A. Williams, “EuroQol—a new facility for the measurement of health-related quality of life,” Health Policy, vol. 16, no. 3, pp. 199–208, 1990. View at Publisher · View at Google Scholar · View at Scopus
  18. S. T. Harris, N. B. Watts, H. K. Genant et al., “Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial,” JAMA, vol. 282, no. 14, pp. 1344–1352, 1999. View at Publisher · View at Google Scholar
  19. R. Lindsay, S. L. Silverman, C. Cooper et al., “Risk of new vertebral fracture in the year following a fracture,” JAMA, vol. 285, no. 3, pp. 320–323, 2001. View at Google Scholar · View at Scopus
  20. F. Salaffi, M. A. Cimmino, N. Malavolta et al., “The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study,” Journal of Rheumatology, vol. 34, no. 7, pp. 1551–1560, 2007. View at Google Scholar
  21. A. K. Oglesby, M. E. Minshall, W. Shen, S. Xie, and S. L. Silverman, “The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women,” Journal of Rheumatology, vol. 30, no. 7, pp. 1579–1583, 2003. View at Google Scholar · View at Scopus
  22. N. M. Van Schoor, J. H. Smit, J. W. R. Twisk, and P. Lips, “Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study,” Osteoporosis International, vol. 16, no. 7, pp. 749–756, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. C. M. Klotzbuecher, P. D. Ross, P. B. Landsman, T. A. Abbott, and M. Berger, “Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis,” Journal of Bone and Mineral Research, vol. 15, no. 4, pp. 721–739, 2000. View at Google Scholar · View at Scopus
  24. G. Lyritis, F. Marin, C. Barker et al., “Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS,” Current Medical Research and Opinion, vol. 26, no. 8, pp. 1799–1807, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. O. Ljunggren, A. Fahrleitner-Pammer, A. Kutahov et al., “Back pain is reduced in postmenopausal women with severe osteoporosis treated with teriparatide regardless of incident fractures,” Journal of Bone and Mineral Research, article S347, 2008. View at Google Scholar
  26. B. Langdahl, O. Ljunggren, W. Lems et al., “Women with severe osteoporosis treated with teriparatide improve quality of life regardless of incident fractures: a 18-month results from European Forsteo Observational Study (EFOS),” Journal of Bone and Mineral Research, article S347, 2008. View at Google Scholar
  27. M. C. Nevitt, P. Chen, R. K. Dore et al., “Reduction risk of back pain following teriparatide treatment: a meta-analysis,” Osteoporosis International, vol. 16, pp. 749–756, 2005. View at Google Scholar
  28. M. C. Nevitt, P. Chen, D. P. Kiel et al., “Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis,” Osteoporosis International, vol. 17, no. 11, pp. 1630–1637, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Adami, D. Maugeri, V. Toscano et al., “Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO),” Clinical and Experimental Rheumatology, vol. 29, no. 3, pp. 477–484, 2011. View at Google Scholar
  30. G. Cizza, S. Primma, M. Coyle, L. Gourgiotis, and G. Csako, “Depression and osteoporosis: a research synthesis with meta-analysis,” Hormone and Metabolic Research, vol. 42, no. 7, pp. 467–482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. Q. Wu, J. H. Magnus, J. Liu, A. F. Bencaz, and J. G. Hentz, “Depression and low bone mineral density: a meta-analysis of epidemiologic studies,” Osteoporosis International, vol. 20, no. 8, pp. 1309–1320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. David, C. B. Confavreux, N. Mehsen, J. Paccou, A. Leboime, and E. Legrand, “Severity of osteoporosis: what is the impact of co-morbidities?” Joint Bone Spine, vol. 77, no. 2, pp. S103–S106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. S. L. Silverman, W. Shen, M. E. Minshall, S. Xie, and K. H. Moses, “Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study,” Journal of Rheumatology, vol. 34, no. 1, pp. 140–144, 2007. View at Google Scholar · View at Scopus
  34. D. Weycker, D. Macarios, J. Edelsberg, and G. Oster, “Compliance with osteoporosis drug therapy and risk of fracture,” Osteoporosis International, vol. 18, no. 3, pp. 271–277, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Kothawala, E. Badamgarav, S. Ryu, R. M. Miller, and R. J. Halbert, “Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis,” Mayo Clinic Proceedings, vol. 82, no. 12, pp. 1493–1501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. N. K. Arden, S. Earl, D. J. Fisher, C. Cooper, S. Carruthers, and M. Goater, “Persistence with teriparatide in patients with osteoporosis: the UK experience,” Osteoporosis International, vol. 17, no. 11, pp. 1626–1629, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Briot, P. Ravaud, P. Dargent-Molina, M. Zylberman, S. Liu-Leage, and C. Roux, “Persistence with teriparatide in postmenopausal osteoporosis; Impact of a patient education and follow-up program: the French experience,” Osteoporosis International, vol. 20, no. 4, pp. 625–630, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. D. Adachi, D. A. Hanley, J. K. Lorraine, and M. Yu, “Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study,” Clinical Therapeutics, vol. 29, no. 9, pp. 2055–2067, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. S. McCombs, P. Thiebaud, C. McLaughlin-Miley, and J. Shi, “Compliance with drug therapies for the treatment and prevention of osteoporosis,” Maturitas, vol. 48, no. 3, pp. 271–287, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. E. S. Siris, S. T. Harris, C. J. Rosen et al., “Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases,” Mayo Clinic Proceedings, vol. 81, no. 8, pp. 1013–1022, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Weycker, D. Macarios, J. Edelsberg, and G. Oster, “Compliance with drug therapy for postmenopausal osteoporosis,” Osteoporosis International, vol. 17, no. 11, pp. 1645–1652, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J. A. Cramer, M. M. Amonkar, A. Hebborn, and R. Altman, “Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis,” Current Medical Research and Opinion, vol. 21, no. 9, pp. 1453–1460, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. J. S. Finkelstein, J. J. Wyland, H. Lee, and R. M. Neer, “Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 4, pp. 1838–1845, 2010. View at Publisher · View at Google Scholar · View at Scopus